After Hours Summary: SSNI +22.6%, NPTN +21.7%, SEDG +15.4%, AMDA -31%, KEYW -21.5%, PLNR -15.2% following earnings/guidance
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: SSNI +22.6%, NPTN +21.7%, SEDG +15.4%, IMPV +12.4%, PLPM +9.7%, WPRT +8.7%, HNSN +8.3%, DATA +8.1%, STMP +7.1%, RBA +6.3%, BKD +5.3%, SAAS +5.3%, CALA +5%, OUTR +5%, ENOC +4.5%, MOH +3.9%, RLYP +3.5%, GSAT +3.5%, RYI +3.3%, ACET +3%, NUAN +2.6%, CYBR +2.5%, SWIR +2.2%, CPXX +2%, PGH +2%, ACAD +1.9%, AIRM +1.9%, XOMA +1.8%, ALSK +1.8%, FUEL +1.7%
Companies trading higher in after hours in reaction to news: NVGN +21.3% (move being attributed to press release regarding the presentation of positive pre-clinical date for TRXE-009 for the treatment of brain cancer), SCMP +6.1% (announced that the FDA has granted Fast Track Designation for Cobiprostone, for the prevention of oral mucositis), AMRN +5.1% (disclosed it filed a lawsuit against the FDA to permit the sharing of 'truthful and non-misleading information' with healthcare professionals in the
US that would be considered off-label), MCRL +2.2% (to be acquired by Microchip Technology (MCHP) for $14 per share), SWIR +2.2% (to acquire connectivity services provider Accel; co also reported earnings), NOK +1.3% (seeing reports that Uber has joined in bidding for co's maps unit; bidding up to $3 bln), BIIB +1.1% (announced Board authorization for a $5 bln share repurchase program, in addition to its existing 1.3 mln share authorization), SYT +0.8% (seeing reports that co may be acquired by Monsanto (MON))
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: AMDA -31%, KEYW -21.5%, PLNR -15.2%, BIOS -15%, FLDM -14.8%, TWOU -14.2%, BEBE -12.3%, SFM -8.6%, DXPE -8.5%, AVNW -7.9%, AVID -7.4%, MDVN -6.3%, UBNT -5.9%, AL -5.5%, SPPI -4.9%, MNST -4.8%, PSIX -4.8%, JAZZ -3.7%, BBOX -3.4%, NOG -3.3%, GALE -2.2%, NVDA -2%, EGY -1.9%, UEPS -1.8%, WAIR -1.6%, FRPT -1.4%, MACK -1.3%, FATE -1.3%, ESPR -1.2%, MCHP -0.9%
Companies trading lower in after hours in reaction to news: LJPC-6.6% (announced it will discontinue development of its polysaccharide-based galectin-3 inhibitors, GCS-100 and LJPC-1010),CNCE -5.2% (co and Jazz Pharmaceuticals (JAZZ) reported results from their Phase 1 clinical study of JZP-386; studies do not support advancing into a later-stage clinical trial of JZP-386 at this time), CEMP -1.7% (filed mixed securities shelf offering), SMLP -0.3% (priced public offering of 6.5 mln common units at $30.75 per unit)